pharma · Knee Osteoarthritis · Hypoplastic Left Heart Syndrome · RGBP
Regeneron Ireland Designated
Regeneron Ireland Designated Activity Company (DAC)
Regeneron Ireland Designated is a pharma organization headquartered in LA MESA, CA, IE. It trades on NYSE under ticker RGBP. Primary therapeutic focus areas include Knee Osteoarthritis, Hypoplastic Left Heart Syndrome, C
LA MESA, CA, IE HQ
Public company Type
RGBP · NYSE Ticker
Company details
- Status
- Public
- HQ
- LA MESA, CA, IE
- Programs
- 10
- Drugs
- 62
- Patents
- 8292
Autologous (self) mononuclear cells derived from umbilical cord blood
Phase 2 · mab · Hypoplastic Left Heart Syndrome
Autologous (self) mononuclear cells derived from umbilical cord blood for Hypoplastic Left Heart Syndrome is a Phase 2 program (mab) at Regeneron Ireland Designated Activity Company (DAC) with 1 ClinicalTrials.gov record(s).
Internal code 18-004753
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Regeneron Ireland Designated Activity Company (DAC)
- Phase
- Phase 2
- Modality
- mab
- Indication
- Hypoplastic Left Heart Syndrome
- Status
- active
- Trials
- 1